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Abstract
Epidemiologic and clinical evidence suggests that virus infection plays an important role in human type 1 diabetes
pathogenesis. We used the virus-inducible BioBreeding Diabetes Resistant (BBDR) rat to investigate the ability of
sodium salicylate, a non-steroidal anti-inflammatory drug (NSAID), to modulate development of type 1 diabetes.
BBDR rats treated with Kilham rat virus (KRV) and polyinosinic:polycytidylic acid (pIC, a TLR3 agonist) develop
diabetes at nearly 100% incidence by ~2 weeks. We found distinct temporal profiles of the proinflammatory serum
cytokines, IL-1β, IL-6, IFN-γ, IL-12, and haptoglobin (an acute phase protein) in KRV+pIC treated rats. Significant
elevations of IL-1β and IL-12, coupled with sustained elevations of haptoglobin, were specific to KRV+pIC and not
found in rats co-treated with pIC and H1, a non-diabetogenic virus. Salicylate administered concurrently with KRV
+pIC inhibited the elevations in IL-1β, IL-6, IFN-γ and haptoglobin almost completely, and reduced IL-12 levels
significantly. Salicylate prevented diabetes in a dose-dependent manner, and diabetes-free animals had no evidence
of insulitis. Our data support an important role for innate immunity in virus-induced type 1 diabetes pathogenesis. The
ability of salicylate to prevent diabetes in this robust animal model demonstrates its potential use to prevent or
attenuate human autoimmune diabetes.
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Introduction
Development of human type 1 diabetes requires a
susceptible genetic background. However, most patients
(~85%) have no family history of the disease and concordance
is only ~50% among identical twins, indicating that expressivity
of type 1 diabetes susceptibility genes is environmentally
dependent [1,2]. Epidemiologic and clinical evidence suggests
virus exposure may be a ‘trigger’ for type 1 diabetes
development [3,4]. Mechanistic studies of virus-induced
diabetes are not feasible in humans, therefore reliable virus-
inducible animal models are needed.
A well-established animal model of virus-inducible type 1
diabetes is the BioBreeding Diabetes Resistant (BBDR) rat.
When treated with the parvovirus Kilham rat virus (KRV) and a
TLR3 agonist, polyinosinic:polycytidylic acid (pIC), BBDR rats
develop diabetes at a high rate (~100%), with consistent
kinetics (~2 weeks) [5,6]. This highly reproducible model allows
us to dissect the progression of disease from viral infection to
onset of hyperglycemia in distinct temporal stages. KRV does
not infect pancreatic beta cells directly, but induces
autoimmune diabetes through alteration of the immune system
[7,8]. Microarray studies of pancreatic lymph nodes from KRV-
infected BBDR rats show upregulation of many
proinflammatory cytokine genes prior to diabetes onset [9]. In
humans, serum levels of proinflammatory cytokines and C-
reactive protein (CRP) are elevated in newly-diagnosed type 1
diabetes patients compared to age-matched controls [10], and
increased TLR expression or responsiveness of PBMCs from
these patients is associated with elevated NF-κB signaling
[11,12].
Mechanistic studies demonstrate inhibition of NF-κB activity
by non-acetylated salicylates, a class of non-steroidal anti-
inflammatory drugs (NSAIDs) [13,14]. The TINSAL-T2D
(Targeting Inflammation using Salsalate for Type 2 Diabetes)
study demonstrated that Salsalate (a prodrug form of
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salicylate) lowers circulating free fatty acids, resulting in
improved glucose and lipid homeostasis [15–17]. These data
support therapeutic targeting of inflammation and NF-κB in type
2 diabetes. We hypothesize that salicylates may also target the
inflammatory components of type 1 diabetes and may be
efficacious in the prevention or treatment of this disease. Here
we utilize the virus-inducible BBDR rat to investigate the ability
of salicylate to modulate the inflammatory innate immune




BBDR rats obtained from Biomedical Research Models, Inc.
were maintained in a viral-antibody-free facility and maintained
in accordance with the Guide for the Care and Use of
Laboratory Animals (Institute of Laboratory Animal Resources,
1996) and guidelines of the Institutional Animal Care and Use
Committee of the University of Massachusetts Medical School
(approval number #A-1766).
Diabetes induction and salicylate treatment
BBDR rats of both sexes aged 21-24 days were injected
intraperitoneally (i.p.) with pIC (Sigma) (1-2 µg/g body weight,
in PBS) for three days (days -3, -2, and -1), followed by a
single i.p. dose of 1x107 PFU of KRV (or non-diabetogenic H1
virus) on day 0. Sodium salicylate (SS, in PBS) (Calbiochem)
was injected i.p. on the same days as pIC (days -3, -2, and -1)
and KRV (day 0). Rats were monitored for glycosuria (Clinistix,
Bayer); diabetes was confirmed by blood glucose >250 mg/dL
on two consecutive days (Accu-Chek, Roche Diagnostics).
Pancreatic histology, insulitis scoring, and
immunofluorescence staining
Rat pancreata were fixed in 10% buffered formalin and
embedded in paraffin. Sections were stained with hematoxylin
and eosin (H&E). Insulitis scores from 0 to 4 were assigned
based on the percent mononuclear infiltration of the islets: 0 =
normal islet, 1 = trace (<10%), 2 = mild (10-30%), 3 = moderate
(30-70%), or 4 = severe (>70%) infiltration. Pancreas sections
were analyzed by a person unaware of the treatment status.
Immunofluorescence staining used mouse anti-glucagon
(Sigma) and guinea pig anti-insulin (DAKO); secondary
antibodies were Alexa-Fluor 488 and 592 goat anti-mouse and
anti-guinea pig (Invitrogen). Images were captured using
spinning-disk confocal microscopy (Nikon Eclipse TE2000-E)
and analyzed with MetaMorph or NIS-Elements AR software.
Serum collection and ELISA analysis
Blood was collected with Trasylol (Sigma) at Day 1, 4, 7, and
11 following virus treatment. Serum was aliquoted and stored
at -80°C until analysis by ELISA for IL-1β, IL-6, IFN-γ
(Signosis), IL-12 (Invitrogen), MCP-1, haptoglobin and insulin
(Alpco).
Statistical analysis
Survival curves were computed by Kaplan-Meier with log-
rank test; all other data were analyzed by ANOVA (GraphPad
Prism 5.0) with Bonferroni post hoc test.
Results
Salicylate treatment prevents KRV+pIC induced type 1
diabetes in a dose-dependent manner
To determine the efficacy of salicylate to prevent virus-
induced diabetes, we treated BBDR rats with KRV+pIC and a
5-fold dose range of sodium salicylate. Co-administration of
350 mg/kg salicylate prevented diabetes onset nearly
completely, and the lowest dose tested (70 mg/kg) resulted in
~25% lower incidence of disease (Figure 1A). Interestingly,
salicylate co-treated rats that developed T1D did so with similar
kinetics (Figure 1A) and blood glucose levels (data not shown)
as the KRV+pIC treated rats. Blood glucose levels of salicylate
co-treated rats that remained diabetes-free were similar to
control rats and significantly different from those of KRV+pIC
treated rats (Figure 1B). All salicylate-treated rats that
remained diabetes-free appeared healthy and gained weight
similar to untreated controls (data not shown), indicating that
no overt toxicity was associated with these doses of salicylate.
To investigate whether the preventative effects of salicylate
treatment was sustainable, a subset of the non-diabetic KRV
+pIC+SS treated rats were monitored for an additional two to
six months: all these rats (n=9) remained healthy and diabetes-
free. In addition, we included a group of rats treated with pIC
and a non-diabetogenic virus, H1. Although H1 and KRV have
98% sequence identity, H1+pIC treatment did not induce
diabetes in this study (n=12), consistent with previous reports
[7,18].
Salicylate reduces serum levels of KRV+pIC induced
proinflammatory cytokines
In order to assess proinflammatory cytokines during diabetes
induction and their potential modulation by salicylate treatment,
serum samples were collected at selected time points after
KRV+pIC treatment in the highest dose groups (280 and 350
mg/kg) of salicylate. To distinguish the contribution of pIC in
modulating the serum cytokine levels of KRV+pIC treated rats,
we included a group treated with pIC only. BBDR rats (n=6)
treated with this low dose of pIC did not develop diabetes, as
we previously reported [18].
KRV+pIC induced significant elevations of IL-1β, IL-6, and
IFN-γ one day after treatment compared to untreated controls
(Figure 2A-C). Yet, in each case, salicylate blocked the initial
KRV+pIC induced elevations in IL-1β, IL-6, and IFN-γ almost
completely. IL-1β and IL-6 levels in rats treated with non-
diabetogenic H1+pIC were not significantly different from those
of untreated controls, whereas IFN-γ levels were elevated
similar to those of KRV+pIC treated rats. In general, serum
levels of cytokines in pIC only treated rats were similar to those
of untreated control rats, with the exception of IL-6, which was
somewhat elevated at day 1, but less than KRV+pIC treated
rats. At all time points analyzed, serum levels of the
Salicylate prevents autoimmune type 1 diabetes
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chemokine, MCP-1, were not statistically different between
untreated and treated groups (data not shown).
In contrast to the rapid induction of IL-1β, IL-6, and IFN-γ in
response to KRV+pIC treatment, IL-12 had much slower
kinetics (Figure 2D). There was no detectable increase in IL-12
at day 1 with KRV+pIC treatment, however, levels were
elevated ~8-fold at day 4 and remained elevated at later time
points when other cytokines had returned towards baseline
levels. Importantly, both non-diabetogenic pIC and H1+pIC
treatments failed to induce IL-12 at any time point analyzed,
suggesting that IL-12 may be indicative of a diabetogenic
inflammatory process. Although salicylate co-treatment did not
completely block elevation of IL-12 in KRV+pIC treated rats,
the levels were significantly ameliorated at days 4 and 11.
Salicylate inhibits KRV+pIC induction of the acute
phase protein, haptoglobin
Using proteomic analyses we previously reported that serum
levels of haptoglobin increased dramatically in BBDR rats
treated with KRV+pIC [18]; here we confirm this finding by
ELISA and further investigate the effect of salicylate to
modulate haptoglobin levels. On day 1, KRV+pIC, H1+pIC, and
pIC only treated rats had a ~15-fold increase in serum
haptoglobin (Figure 3). Although haptoglobin levels in H1+pIC
and pIC only treated rats subsequently declined, the levels in
KRV+pIC treated rats remained elevated through day 7. At all
time points analyzed, however, salicylate treatment completely
blocked the KRV+pIC induced increase in serum haptoglobin.
Normal islet morphology and insulin staining in KRV
+pIC and salicylate-treated rats that remain diabetes-
free
To investigate the effect of salicylate treatment within the
target organ, pancreata of treated rats were collected at
selected time points and processed for morphology and insulin/
glucagon staining. Consistent with earlier reports [19],
lymphocytic infiltration of pancreatic islets (insulitis) of KRV
+pIC treated rats was not detectable until day 11, with severe
insulitis noted at day 14 (Figure 4A-B). In contrast, islets of all
non-diabetic KRV+pIC+SS treated rats examined on day 14,
Figure 1.  Sodium salicylate improves blood glucose levels and diabetes-free survival of KRV+pIC treated rats.  BBDR rats
were pre-treated with pIC and 0 to 350 mg/kg of sodium salicylate (SS) for 3 consecutive days (-3, -2, -1); KRV treatment and an
additional treatment with SS was given on day 0. Doses of SS from 70 to 350 mg/kg body weight corresponded to 2- to 10-fold the
amount given daily (for 14 weeks) to TINSAL-T2D patients [16]. (A) Kaplan-Meier curve showing onset of diabetes. As expected,
>90% of rats given KRV+pIC without SS treatment became diabetic by 14-18 days, ***p<0.001. (B) Blood glucose levels were
measured at the indicated times; n=6 for all groups, untreated (white), KRV+pIC (red), and KRV+pIC+SS (green); ***p<0.001, KRV
+pIC vs. untreated and KRV+pIC+SS groups.
doi: 10.1371/journal.pone.0078050.g001
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regardless of SS dose, had no detectable insulitis and were
morphologically indistinguishable from untreated age-matched
control rats. Pancreata of BBDR rats treated with pIC only or
H1+pIC had normal islet morphology and insulin staining at day
14 as well (data not shown).
As expected, increasing severity of insulitis correlated with a
progressive loss of insulin staining in KRV+pIC treated rats
(Figure 4C-D). Concomitant with the loss of insulin staining in
the islets, circulating levels of serum insulin also progressively
declined (Figure 4E). In contrast, insulin staining of islets from
non-diabetic KRV+pIC+SS treated rats was similar to control
rats (Figure 4C-D), as were serum insulin levels (Figure 4E).
Discussion
In this study we utilized the virus-inducible BBDR rat model
to examine the effects of salicylate treatment to modulate type
1 diabetes progression. To our knowledge this study is the first
to investigate the effects of NSAID on autoimmune type 1
diabetes pathogenesis. First, type 1 diabetes was prevented in
a dose-dependent manner by treatment with the NSAID,
salicylate. Second, we established distinct temporal profiles of
selected inflammatory cytokines (IL-1β, IL-6, IL-12, and IFN-γ)
and haptoglobin in the sera of BBDR rats in response to KRV
+pIC treatment; significant elevations of IL-1β and IL-12,
coupled with sustained elevations of haptoglobin, were specific
to KRV+pIC and not found in rats co-treated with pIC and H1, a
non-diabetogenic virus. Third, doses of salicylate that
prevented diabetes also blocked or reduced elevations in these
inflammatory cytokines and haptoglobin. Fourth, the pancreata
of KRV+pIC+SS treated rats that remained diabetes-free
showed normal islet morphology and insulin staining, and the
islets were free of detectable insulitis. Fifth, SS treatment led to
permanent protection from diabetes, even after withdrawal of
the drug. Collectively, these data underscore the importance of
the initial innate immune response in the pathogenesis of virus-
inducible diabetes, and highlight the need to develop new
diabetes therapies that target the inflammatory innate immune
response.
Gene expression and genetic association studies support an
emerging link between the innate immune response and
susceptibility to human type 1 diabetes. An interferon
regulatory factor 7-driven inflammatory network (IDIN) enriched
for viral response genes has been identified in the BB rat [20],
Figure 2.  Proinfammatory cytokines are reduced in salicylate treated BBDR rats that remained diabetes-free.  BBDR rats
were untreated (vertical), pre-treated with pIC alone (hatched), H1+pIC (clear), KRV+pIC (black), or KRV+pIC+SS (diagonal).
Serum samples were collected from rats at 1, 4, 7, and 11 days following KRV or H1 treatment and analyzed for (A) IL-1β. (B) IL-6,
(C) IFN-γ, and (D) IL-12. Untreated control, n=3; mean values of control rats for IL-1β. IL-6, IFN-γ, and IL-12 were 1.85, 0.54, 2.07,
and 0.47 ng/ml, respectively. For all treated groups, n≥6. Mean and standard error are shown; *p<0.05; **p<0.01; ***p<0.001.
doi: 10.1371/journal.pone.0078050.g002
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and genes from the analogous human IDIN have been shown
to associate with susceptibility to type 1 diabetes [21]. In
addition, a human genome-wide SNP scan identified the viral
RNA receptor gene region IFIH1 (interferon induced with
helicase C domain 1) as a type 1 diabetes susceptibility gene.
Higher IFIH1 gene expression levels are found in the PBMCs
of individuals with the susceptible genotype, and signaling
through IFIH1 activates interferon-regulatory and other
transcription factors (e.g., NF-κB) that, in turn, affect the levels
and types of cytokines produced [22]. Our data indicate that
elevations in IL-1β and IL-12 at the initial stages of KRV+pIC
treatment, coupled with sustained elevations of haptoglobin,
are associated with progression to diabetes in BBDR rats.
A recent functional genomics study of human sera found the
importance of IL-1 in type 1 diabetes pathogenesis [23],
supporting the relevance of our cytokine data obtained from the
BBDR rat. Innate immune response and IL-1 regulated genes
were identified in PBMCs incubated with sera from recent-
onset type 1 diabetes patients, but not from sera of long-
standing diabetes patients or healthy controls [23]. Moreover,
even in pre-diabetic children, multiple proinflammatory
cytokines, including IL-1β and IL-12, were significantly higher in
children positive for islet autoantibodies compared to age-
matched autoantibody-negative control subjects [24].
In our study, salicylate blocked or reduced the KRV+pIC
induced elevations of serum proinflammatory cytokines and the
acute phase protein, haptoglobin. Similarly, the acute phase
protein, CRP, was reduced in type 2 diabetes patients given
salsalate in the TINSAL-T2D study [16]. In both cases,
salicylates likely prevent or ameliorate diabetes by reducing the
magnitude of the inflammatory innate immune response.
Speculatively, ‘hyperactivation’ of the innate immune system
may reach a threshold above which, in genetically-susceptible
individuals, an islet-specific adaptive (auto) immune response
is engaged that progresses to type 1 diabetes. As such, in
those patients at-risk for type 1 diabetes, we envision that
‘preventative’ treatment may only require salicylate treatment
transiently, when patients have evidence of an infection (e.g.,
fever). In this case, salicylate could be given short term (e.g.,
several days) to dampen the innate inflammatory response, yet
still allow for clearance of the virus/pathogen.
In summary, the BBDR model is a powerful tool to elucidate
the causes and consequences in virus-inducible autoimmune
diabetes. The similar serum cytokines in human type 1
diabetes and virus-induced BBDR rats support the use of this
model for identifying cellular and molecular mechanisms
involved, as well as pre-clinical testing of type 1 diabetes
therapeutics for safety and efficacy. Our novel discovery
provides insight into the potential use of salicylate as a stand-
alone or combination therapy to prevent and/or treat human
type 1 diabetes. Given the well-known safety record for
salicylate, its use in clinical trials of pre-diabetic or recent-onset
patients may be warranted.
Figure 3.  Salicylate blocks induction of the acute phase protein, haptoglobin.  BBDR rats were untreated (vertical), pre-
treated with pIC alone (hatched), H1+pIC (clear), KRV+pIC (black), or KRV+pIC+SS (diagonal). Serum samples were collected from
rats at 1, 4, 7, and 11 days following KRV treatment and analyzed for haptoglobin. Untreated control, n=3; all treated groups, n≥6.
Mean and standard error are shown; **p<0.01; ***p<0.001.
doi: 10.1371/journal.pone.0078050.g003
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Figure 4.  Insulitis and subsequent loss of islet and serum insulin are completely abrogated in salicylate treated BBDR rats
that remained diabetes-free.  BBDR rats were untreated or treated with KRV+pIC ± SS. (A) Pancreas samples were collected at
the times indicated and stained for H&E (arrows indicate infiltrating lymphocytes). Panels shown are representative of n≥6 rats per
group; scale bar, 50 µm. (B) Insulitis scores were determined from pancreas sections of 6-10 rats per group, 10-25 islets per rat. (C)
Pancreas samples were collected and stained for insulin (green), glucagon (red), and DNA (DAPI, blue). Left panels are from an
untreated (Control) BBDR rat, middle panels are from KRV+pIC treated rats at onset of insulitis (day 11) and hyperglycemia (day
14), and right panels are from a KRV+pIC+SS treated rat that was diabetes-free at day 14. Panels shown are representative of n≥3
rats per group; scale bar, 50 µm. (D) Insulin to DNA ratio is represented by green to blue intensity ratio; mean and standard error
were calculated with n=9 islets per group, ***p<0.001, KRV+pIC vs. Control and KRV+pIC+SS groups. (E) Circulating serum levels
of insulin were assayed at the indicated times; mean and standard error were calculated from n=6 rats per group, ***p<0.001, KRV
+pIC vs. Control and KRV+pIC+SS groups.
doi: 10.1371/journal.pone.0078050.g004
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